Phase 1 single ascending dose escalation study of TNX-1500 in healthy volunteers
Latest Information Update: 06 Mar 2024
At a glance
- Drugs TNX 1500 (Primary)
- Indications Autoimmune disorders; Graft-versus-host disease; Renal transplant rejection; Transplant rejection
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
- Sponsors Tonix Pharmaceuticals Inc
- 05 Mar 2024 According to Tonix Pharmaceuticals Holding Corp media release, the Phase 1 trial is intended to support dosing in a planned Phase 2 trial in kidney transplant recipients.
- 05 Mar 2024 According to Tonix Pharmaceuticals Holding Corp media release, company is looking forward to the results of Phase 1 PK and pharmacodynamic trial in the third quarter of 2024.
- 28 Feb 2024 According to Tonix Tonix Pharmaceuticals media release, announced the completion of the clinical stage of its Phase 1, single ascending dose escalation trial of TNX-1500 in healthy volunteers.